Core Viewpoint - Veritone, Inc. announced a proposed underwritten public offering of shares of its common stock, intending to use the net proceeds for working capital and general corporate purposes, including debt service and repayment of indebtedness [1] Group 1 - The company is a leader in building human-centered enterprise AI solutions [1] - The offering is subject to market and other conditions, with no assurance of completion [1]

Core Points - Invivyd, Inc. announced a public offering of 74,811,404 shares of common stock at $0.52 per share, along with pre-funded warrants for 21,342,442 shares at $0.5199 each, aiming for gross proceeds of approximately $50 million [1][3] - The offering is expected to close on or about August 22, 2025, subject to customary closing conditions [1] - Cantor is acting as the sole book-running manager for the offering [2] Use of Proceeds - The net proceeds will be utilized for trial protocol development and advancement of the VYD2311 clinical program, research and development for pipeline programs including RSV and measles, and efforts related to monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome [3] Company Overview - Invivyd, Inc. is a biopharmaceutical company focused on protection against serious viral infectious diseases, starting with SARS-CoV-2, and has a proprietary technology platform for developing antibodies [7]

Core Viewpoint - Invivyd, Inc. has initiated an underwritten public offering of its common stock, with an option for underwriters to purchase an additional 15% of the shares sold at the public offering price [1][3]. Group 1: Offering Details - The offering is subject to market conditions and there is no assurance regarding its completion or the actual size and terms [1]. - Cantor is acting as the sole book-running manager for the offering [2]. - The offering will be conducted under a shelf registration statement filed with the SEC, which was declared effective on October 5, 2022 [4]. Group 2: Use of Proceeds - Invivyd plans to use the net proceeds from the offering for trial protocol development, advancement of the VYD2311 clinical program, and research related to its pipeline programs, including RSV and measles [3]. - Additional uses of the proceeds include efforts related to monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome, as well as general corporate purposes [3]. Group 3: Company Background - Invivyd, Inc. is a biopharmaceutical company focused on providing protection against serious viral infectious diseases, starting with SARS-CoV-2 [7]. - The company utilizes a proprietary technology platform to develop and adapt antibodies, and received emergency use authorization for a monoclonal antibody in March 2024 [7].

Core Viewpoint - SPX Technologies, Inc. has announced a public offering of 2,659,575 shares of its common stock at a price of $188.00 per share, aiming to raise approximately $500 million in gross proceeds before expenses [1]. Group 1: Offering Details - The offering consists of shares sold entirely by SPX, with an additional 30-day option for underwriters to purchase up to 398,936 additional shares [1]. - The expected closing date for the offering is around August 14, 2025, pending customary closing conditions [1]. Group 2: Underwriters - BofA Securities, J.P. Morgan, and Wells Fargo Securities are serving as joint book-running managers for the offering [2]. - TD Cowen and Truist Securities are also acting as book-running managers, with several other firms participating as co-managers [2]. Group 3: Regulatory Information - The shares are being offered under an effective automatic shelf registration statement previously filed with the U.S. Securities and Exchange Commission (SEC) [3]. - A prospectus supplement and accompanying prospectus will be filed with the SEC and made available on their website [3]. Group 4: Company Overview - SPX Technologies, Inc. is a diversified global supplier of engineered products and technologies, with a strong presence in the HVAC and detection and measurement markets [5]. - The company is headquartered in Charlotte, North Carolina, and employs over 4,300 people across more than 16 countries [5].

Core Viewpoint - Compass Therapeutics, Inc. has announced a public offering of its common stock and pre-funded warrants to raise capital for commercial readiness, research, and clinical development of its product candidates [1][2]. Group 1: Offering Details - The public offering includes common stock and pre-funded warrants, with all shares being offered by Compass [1]. - Compass plans to grant underwriters a 30-day option to purchase additional shares under the same terms [1]. - The offering is subject to market conditions, and there is no assurance regarding its completion or the actual size and terms [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for initial preparations for commercial readiness, funding research and clinical development of product candidates, and general corporate purposes [2]. Group 3: Company Overview - Compass Therapeutics is a clinical-stage biopharmaceutical company focused on oncology, developing proprietary antibody-based therapeutics for multiple diseases [5]. - The company’s scientific focus includes the relationship between angiogenesis, the immune system, and tumor growth, with a robust pipeline targeting critical biological pathways for effective anti-tumor responses [5]. - Founded in 2014 and headquartered in Boston, Massachusetts, Compass aims to advance its product candidates through clinical development as standalone therapies and in combination with other proprietary antibodies [5].

Core Viewpoint - Ramaco Resources, Inc. successfully closed a public offering of Class A common stock, raising approximately $200 million to fund its development projects and strategic growth opportunities [1][3]. Group 1: Offering Details - The company sold 10,666,667 shares of Class A common stock at a price of $18.75 per share, resulting in gross proceeds of around $200 million before expenses [1]. - Yorktown Energy Partners, as selling stockholders, granted underwriters a 30-day option to purchase additional shares worth up to $30 million, which was fully exercised [2]. - The sale of additional shares is expected to be completed on August 8, 2025, with no proceeds going to the company from this sale [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to accelerate the development of the company's rare earth elements and critical minerals project, as well as for strategic growth opportunities and general corporate purposes [3]. Group 3: Company Overview - Ramaco Resources operates in southern West Virginia and southwestern Virginia, focusing on high-quality metallurgical coal and developing rare earth and critical minerals in Wyoming [6]. - The company has four active metallurgical coal mining complexes and is in the initial stages of production for a rare earth and coal mine in Wyoming, where a significant deposit of primary magnetic rare earths was discovered [6].

The securities described above are being offered by the Company pursuant to an effective shelf registration statement on Form S-3 (File No. 333-273829) initially filed with the Securities and Exchange Commission ("SEC") on August 9, 2023 and declared effective by the SEC on August 25, 2023. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the offering will be filed with the SEC. Electronic copies of the preliminary prospectus supplement and the accompanying pros ...

Core Viewpoint - Oriental Rise Holdings Limited is conducting a public offering of up to 14,800,000 Units at a price of US$0.4681 per Unit, aiming to raise approximately US$6.9 million for various corporate purposes [1][2]. Group 1: Offering Details - The Offering consists of Units that include one Ordinary Share and one Common Warrant, with the Common Warrant exercisable at the same price as the Unit [1]. - The Common Warrants will have a downward adjustment in exercise price to 70% and 50% of the initial price on the 5th and 10th trading days post-closing, respectively [1]. - The Offering is expected to close on July 23, 2025, subject to customary closing conditions [2]. Group 2: Use of Proceeds - Proceeds from the Offering will be allocated for general corporate purposes, working capital, sales network expansion, and production capacity enhancement [2]. Group 3: Company Overview - Oriental Rise Holdings Limited is an integrated supplier of white and black tea products in mainland China, with operations covering cultivation, processing, and sales [6]. - The company operates tea gardens in Zherong County, Ningde City, Fujian Province, focusing on both wholesale and retail markets [6].

Core Viewpoint - OceanPal Inc. has announced the pricing of its upsized public offering of 10,975,600 units at a price of US$1.64 per unit, aiming to raise approximately US$18.0 million before expenses [1][3]. Group 1: Offering Details - Each unit in the offering consists of one common share and one warrant to purchase one common share [1]. - The warrants will expire three years from issuance and are immediately exercisable at an initial price equal to 225% of the public offering price, with adjustments on specified reset dates [2]. - The offering is expected to close on July 22, 2025, pending customary closing conditions [3]. Group 2: Company Overview - OceanPal Inc. is a global provider of shipping transportation services, focusing on the ownership and operation of dry bulk vessels and product tankers [6]. - The company specializes in the seaborne transportation of bulk commodities such as iron ore, coal, and grain, as well as refined petroleum products [6]. - OceanPal's fleet primarily operates on time charter trips with short to medium durations and spot charters, aiming to maximize long-term shareholder value [6].

Core Viewpoint - Civista Bancshares, Inc. has announced a public offering of 3,294,120 common shares priced at $21.25 per share, aiming for an aggregate amount of $70.0 million, with an option for underwriters to purchase an additional 494,118 shares [1][2]. Group 1: Offering Details - The gross proceeds from the offering are expected to be approximately $70.0 million before discounts and expenses, potentially increasing to $80.5 million if the underwriters fully exercise their option [2]. - The offering is anticipated to close on July 14, 2025, subject to customary closing conditions [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for general corporate purposes, which may include supporting organic growth opportunities and future strategic transactions [2]. Group 3: Management and Registration - Piper Sandler & Co. is the sole book-running manager for the offering, with several firms serving as co-managers [3]. - Civista has filed a shelf registration statement with the SEC, including a preliminary prospectus supplement for the offering [4]. Group 4: Company Overview - Civista Bancshares, Inc. is a financial services holding company with assets of $4.1 billion, headquartered in Sandusky, Ohio, and operates 42 locations across Ohio, Southeastern Indiana, and Northern Kentucky [6].